Phio reports Phase 1b data: complete & partial responses in cutaneous SCC patients

Phio Pharmaceuticals Corp.

Intratumoral PH-762 well tolerated with no related adverse events or dose-limiting toxicities across 5 patients.
Cohort 2: 1 complete response (100% tumor clearance) and 1 partial response (90% tumor clearance) in cutaneous squamous cell carcinoma.
Phase 1b trial ongoing; enrollment anticipated to complete in Q3 2025.
Data presented at SITC 2024 annual meeting in Houston, TX.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.